LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.
MedPharm is a contract provider of topical and transdermal product design and formulation development services.
The biotechnology company said the partnership is the part of its second clinical programme to address the problem of anti-microbial resistance.
The XF platform has already been used in a second phase study of XF-73 nasal gel, which is used for the prevention of post-surgical infections. Destiny said it will begin phase 2b testing of XF-73 in 2019.
MedPharm will develop new formulations containing Destiny's XF-platform compounds for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections, Destiny said.
"There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced level of antimicrobial resistance. We look forward to developing improved, targeted formulations with MedPharm to take into future pre-clinical and clinical studies," said Destiny Chief Executive Neil Clark.
Destiny shares were trading 0.6% higher on Wednesday at 83.00 pence each.
Destiny Pharma. (DEST)